Piramal Pharma Begins $90 Mn Expansion of US Manufacturing Sites
The expansion is aimed at boosting commercial-scale manufacturing capabilities and improving both capacity and operational efficiency at the two facilities.
Piramal Pharma Solutions, a leading Indian contract development and manufacturing organization (CDMO), has announced a $90 Mn investment to expand its US operations across two sites, Riverview, Michigan, and Lexington, Kentucky.
The expansion is aimed at boosting commercial-scale manufacturing capabilities and improving both capacity and operational efficiency at the two facilities. These sites form a critical part of Piramal Pharma’s integrated antibody-drug conjugate (ADC) platform, ADCelerate.
The Riverview facility, which focuses on drug substance development and high potency active pharmaceutical ingredients (HPAPIs), plays a pivotal role in producing payload-linkers, key components in ADC therapies that combine chemotherapy with monoclonal antibodies.
This site will receive a new commercial-scale suite for payload-linker development and manufacturing, slated to be operational by the end of 2025.
Meanwhile, the Lexington site, Piramal’s dedicated fill/finish facility for sterile injectable drugs, will undergo a 24,000 sq ft expansion. This includes a new lab and the addition of advanced machinery such as a new filling line, two large lyophilizers, a high-end capping machine, and an external vial washer.
Upon completion, the site’s manufacturing capacity will more than double, from 104 to over 240 product batches annually. The expansion is expected to be completed by late 2027 and will create 40 full-time jobs in the region.
These developments align with the growing demand for domestic pharmaceutical manufacturing and strengthen Piramal Pharma’s role in enhancing US supply chain resilience. The groundbreaking ceremony for the Lexington expansion took place on June 25, 2025.
The investment comes amid strong growth in the sterile injectables market, driven by greater medical need, expanding regulatory approvals, and scientific advances. ADCs, in particular, are becoming a prominent treatment option due to their precision and effectiveness in targeting cancers.
Nandini Piramal, Chairperson of Piramal Pharma, highlighted this growth trend, “The sterile injectables market is projected to exceed $20 billion by 2028,” she said.
Peter DeYoung, CEO of Piramal Global Pharma, pointed to the rising relevance of ADCs, “Antibody-drug conjugates are rapidly emerging as effective precision immunotherapy for cancers and tumors,” he said, reaffirming the company’s commitment to evolving with market needs.
Lexington Mayor Linda Gorton welcomed the development, saying it reflects the city’s strength as a business hub and its growing presence in the pharmaceutical sector. “It positions Lexington as a strong business environment and a developing leader in the pharmaceutical industry,” she noted.
Stay tuned for more such updates on Digital Health News
